Literature DB >> 30910808

Acute liver injury induced by red yeast rice supplement.

Lize Loubser1, Kirstin I Weider1, Sean M Drake1.   

Abstract

A 64-year-old woman previously taking no medications presented with acute hepatitis 6 weeks after starting a red yeast rice supplement to decrease her cholesterol. Red yeast rice is commonly used for hyperlipidaemia as an alternative to statins as it contains monacolin K, the same active chemical in lovastatin. Infectious, toxic and autoimmune causes for injury were ruled out, and liver biopsy was consistent with drug induced liver injury. Red yeast rice appeared to be the cause of her hepatotoxicity. After stopping the supplement and initiating treatment with intravenous methylprednisolone, liver enzymes decreased towards baseline. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  hepatitis other; unwanted effects/adverse reactions; vitamins and supplements

Mesh:

Substances:

Year:  2019        PMID: 30910808      PMCID: PMC6510127          DOI: 10.1136/bcr-2018-227961

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  4 in total

1.  Symptomatic hepatitis associated with the use of herbal red yeast rice.

Authors:  Harry Roselle; Andrew Ekatan; Jausheng Tzeng; Mark Sapienza; Jeffrey Kocher
Journal:  Ann Intern Med       Date:  2008-10-07       Impact factor: 25.391

2.  Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system.

Authors:  Gabriela Mazzanti; Paola Angela Moro; Emanuel Raschi; Roberto Da Cas; Francesca Menniti-Ippolito
Journal:  Br J Clin Pharmacol       Date:  2017-01-19       Impact factor: 4.335

3.  Variability in strength of red yeast rice supplements purchased from mainstream retailers.

Authors:  Pieter A Cohen; Bharathi Avula; Ikhlas A Khan
Journal:  Eur J Prev Cardiol       Date:  2017-06-23       Impact factor: 7.804

4.  CSH guidelines for the diagnosis and treatment of drug-induced liver injury.

Authors:  Yue-Cheng Yu; Yi-Min Mao; Cheng-Wei Chen; Jin-Jun Chen; Jun Chen; Wen-Ming Cong; Yang Ding; Zhong-Ping Duan; Qing-Chun Fu; Xiao-Yan Guo; Peng Hu; Xi-Qi Hu; Ji-Dong Jia; Rong-Tao Lai; Dong-Liang Li; Ying-Xia Liu; Lun-Gen Lu; Shi-Wu Ma; Xiong Ma; Yue-Min Nan; Hong Ren; Tao Shen; Hao Wang; Ji-Yao Wang; Tai-Ling Wang; Xiao-Jin Wang; Lai Wei; Qing Xie; Wen Xie; Chang-Qing Yang; Dong-Liang Yang; Yan-Yan Yu; Min-de Zeng; Li Zhang; Xin-Yan Zhao; Hui Zhuang
Journal:  Hepatol Int       Date:  2017-04-12       Impact factor: 6.047

  4 in total
  4 in total

1.  Decreased Risk of Stroke in People Using Red Yeast Rice Prescriptions (LipoCol Forte®): a Total Population-Based Retrospective Cohort Study.

Authors:  Chuen-Chau Chang; Mao-Feng Sun; Yi-Chun Chou; Chun-Chieh Yeh; Chaur-Jong Hu; Yih-Giun Cherng; Ta-Liang Chen; Chien-Chang Liao
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-23       Impact factor: 2.650

Review 2.  Red Yeast Rice Preparations Reduce Mortality, Major Cardiovascular Adverse Events, and Risk Factors for Metabolic Syndrome: A Systematic Review and Meta-analysis.

Authors:  Rong Yuan; Yahui Yuan; Lidan Wang; Qiqi Xin; Ya Wang; Weili Shi; Yu Miao; Sean Xiao Leng; Keji Chen; Weihong Cong
Journal:  Front Pharmacol       Date:  2022-02-21       Impact factor: 5.810

Review 3.  Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds.

Authors:  Je-Wen Liou; Hemalatha Mani; Jui-Hung Yen
Journal:  Int J Mol Sci       Date:  2022-03-31       Impact factor: 5.923

4.  Red yeast rice (Monascus purpureus) supplements: Case series assessment of spontaneously reported cases to The Netherlands Pharmacovigilance Centre Lareb.

Authors:  Misha F Vrolijk; Sonja van de Koppel; Florence van Hunsel
Journal:  Br J Clin Pharmacol       Date:  2020-11-18       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.